Treprostinil study for Raynaud's attacks
Part of Heart & circulation, Skin clinical trials.
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have had 4 or more Raynaud's attacks per week in the last month, even with treatment
- You have primary Raynaud's or Raynaud's due to a connective tissue disease (like scleroderma, lupus, or Sjogren's)
- If you take certain medications (like sildenafil or calcium channel blockers), your dose has been stable for at least 3 months
- You are not pregnant, breastfeeding, or planning pregnancy in the next 4 months
- You do not have uncontrolled high blood pressure, diabetes, recent heart problems, or certain other medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether treprostinil (Remodulin®) can reduce injury to a transplanted kidney right after surgery. If it works and is safe, it may help improve outcomes for people receiving a deceased-donor kidney transplant.
This study tests an inhaled medication called treprostinil to see if it can reduce the number and severity of Raynaud's attacks in people with scleroderma (systemic sclerosis). If you have frequent Raynaud's attacks, this treatment might help you.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Hear when a new Raynaud's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.